Clinical trials: Acute Myeloid Leukemia, in Relapse
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia, Childhood, Relapsed Leukemia
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
This study is a prospective, single-center, single-arm exploratory clinical study, aiming to complete the preliminary clinical observation of 12 children with relapsed/refractory acute myeloid leukemia treated with JK500 cell…
- Conditions
- Acute Myeloid Leukemia, Childhood, Relapsed Leukemia, Refractory Leukemia
- Trial name
- NCT05519384
- Testing
- JK500 cell injection，cyclophosphamide，Fludarabine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
This is a multicenter open-label phase II trial of high dose imatinib mesylate in patients with AML in first or second relapse, or with refractory disease.
- Trial name
- NCT00707408
- Testing
- Imatinib
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Acute Myeloid Leukemia, AML
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.
- Trial name
- OPAL (NCT00780598)
- Testing
- Tosedostat
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- Chroma Therapeutics
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating patients with acute myeloid leukemia that has…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04774393
- Testing
- Decitabine and Cedazuridine, Enasidenib, Ivosidenib
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
- Trial name
- NCT06880354
- Testing
- CLL1 and CD38 Dual-Target CAR-T Cell Injection
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed / Refractory AML, Relapsed / Refractory MDS
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
This is the first-in-human trial with BYON4413 to evaluate safety, PK, immunogenicity, and anti-leukemia activity of BYON4413 in patients with AML or MDS.
- Trial name
- NCT06359002
- Testing
- BYON4413
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 16 people
- Sponsor
- Byondis B.V.
Neoplasm, Stomach, Gastric Neoplasms Malignant
Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)
This is a phase Ib/II clinical study that has two phases. In phase Ib, the safety evaluation of the extract of Petiveria alliacea (Esperanza) will be carried out in patients with metastatic gastrointestinal tumors (colon…
- Conditions
- Neoplasm, Stomach, Gastric Neoplasms Malignant, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- PA001 (NCT05587088)
- Testing
- Petiveria Alliacea Preparation
- Where
- Colombia
- Volunteers
- 82 people
- Sponsor
- Hospital Universitario San Ignacio
Refractory Leukemia, Acute Myelogenous Leukemia
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.
- Trial name
- NCT00880269
- Testing
- Panobinostat/LBH589
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of vorinostat when given together with cytarabine and etoposide in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndromes or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00357305
- Testing
- vorinostat, cytarabine, etoposide
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
- Trial name
- NCT05772273
- Testing
- Azacitidine, Donor lymphocyte infusion, Camrelizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Study of TCP-ATRA for Adult Patients With AML and MDS
Acute Myeloid Leukemia (AML) is a diverse disease that is fatal in the majority of patients. Acute promyelocytic leukemia (APL) however, a subtype of AML accounting for 5% of all cases, is very curable.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Leukemia
- Trial name
- TCP-ATRA (NCT02273102)
- Testing
- Tranylcypromine, Tretinoin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Miami
Leukemia
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of…
- Trial name
- NCT00469859
- Testing
- cytarabine, idarubicin, lestaurtinib
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Children's Oncology Group
Secondary AML, Myelofibrosis
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned…
- Trial name
- NCT07250646
- Testing
- rebecsinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aspera Biomedicines, Inc.
AML, MDS
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
- Trial name
- NCT04017546
- Testing
- CYC065, Venetoclax
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
The purpose of this study is to test the safety and determine the best dose of venetoclax and selinexor when given with chemotherapy drugs in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04898894
- Testing
- Venetoclax, Selinexor, Cytarabine
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/ Recommended Phase 2 Doses (RP2D(s)) of…
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT03755154
- Testing
- S65487- initial scheme, S65487 - alternative scheme
- Where
- 11 sites in Australia, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Institut de Recherches Internationales Servier
Breast Cancer, Chronic Myeloproliferative Disorders
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
RATIONALE: Understanding the emotional needs of spouses or others who are living with and caring for patients who have undergone stem cell transplantation may help improve the quality of life of both the caregivers and the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00082654
- Testing
- psychosocial assessment and care
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Acute Myeloid Leukemia
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
This Phase Ib study is designed to evaluate the safety and pharmacokinetics of atezolizumab when given in combination with Hu5F9-G4 to patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT03922477
- Testing
- Atezolizumab, Hu5F9-G4
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.